The initiation of coverage by a reputable analyst firm like Evercore ISI Group with an Outperform rating and a significant price target of $65 suggests a strong bullish outlook for Jasper Therapeutics. This is likely to generate positive investor sentiment and could lead to a short-term increase in the stock price, given the high relevance and importance of such analyst coverage in the investment community.